Apuli Maricel 4

What Happened
Apuli Maricel, Chief Accounting Officer of BridgeBio Pharma, sold 2,000 shares of BBIO in an open-market transaction on April 30, 2026, at $71.58 per share, for total proceeds of $143,160. This was a sale (S), not a purchase.

Key Details

• Transaction date and price: 2026-04-30 — 2,000 shares @ $71.58 each (total $143,160).
• Transaction type: Sale (open market or private sale per filing).
• Footnote: Transaction was effected under a Rule 10b5-1 sales plan adopted by the reporting person on September 8, 2025 (preplanned sale).
• Filing date: Report filed 2026-05-04 (filed within the 2-business-day Form 4 window for an Apr 30 transaction).
• Shares owned after the transaction: Not specified in the provided filing.

Context
Sales executed under a 10b5-1 plan are prearranged and typically routine, so they do not necessarily indicate a change in the insider’s view of the company. For retail investors, purchases by insiders can be more informative than single, preplanned sales; this transaction should be viewed as a routine disposition unless additional filings indicate otherwise.